Richard G Gorlick

Summary

Affiliation: Montefiore Medical Center
Country: USA

Publications

  1. doi request reprint Children's Oncology Group's 2013 blueprint for research: bone tumors
    Richard Gorlick
    The Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10467, USA
    Pediatr Blood Cancer 60:1009-15. 2013
  2. pmc Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program
    Richard Gorlick
    The Children s Hospital at Montefiore, Bronx, NY 10467, USA
    Pediatr Blood Cancer 59:1266-74. 2012
  3. pmc Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program
    Richard Gorlick
    The Children s Hospital at Montefiore, Bronx, New York, USA
    Pediatr Blood Cancer 59:518-24. 2012
  4. pmc Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier
    Rui Yang
    Department of Pediatrics and Molecular Pharmacology R, Y, R, G, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, NY 10461, USA
    BMC Cancer 8:124. 2008
  5. doi request reprint Current concepts on the molecular biology of osteosarcoma
    Richard Gorlick
    The Albert Einstein College of Medicine of Yeshiva University, The Children s Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal 3rd Floor, Bronx, NY 10467, USA
    Cancer Treat Res 152:467-78. 2009
  6. doi request reprint Osteosarcoma
    Richard Gorlick
    Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine, Yeshiva University, Department of Pediatrics, Children s Hospital at Montefiore, Bronx, NY 10467, USA
    J Bone Miner Res 25:683-91. 2010
  7. ncbi request reprint Leydig cell tumor after treatment for Ewing's sarcoma
    Linda J Butros
    Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
    Pediatr Blood Cancer 49:1008-10. 2007
  8. ncbi request reprint Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience
    Alexander J Chou
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:2214-21. 2005
  9. ncbi request reprint Impairments in antifolate transport are common in retinoblastoma tumor samples
    Richard G Gorlick
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:573-6. 2008
  10. ncbi request reprint Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience
    LeLe Aung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 95:1728-34. 2002

Research Grants

  1. ANTIFOLATE RESISTANCE OSTEOSARCOMA
    Richard Gorlick; Fiscal Year: 2001
  2. Antifolate Resistance in Osteosarcoma
    Richard Gorlick; Fiscal Year: 2007

Collaborators

Detail Information

Publications10

  1. doi request reprint Children's Oncology Group's 2013 blueprint for research: bone tumors
    Richard Gorlick
    The Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine of Yeshiva University, Bronx, NY 10467, USA
    Pediatr Blood Cancer 60:1009-15. 2013
    ..Trials planned by the Children's Oncology Group will investigate new target(s) including IGF-1R and mTOR in ES, and RANKL and GD2 in osteosarcoma...
  2. pmc Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program
    Richard Gorlick
    The Children s Hospital at Montefiore, Bronx, NY 10467, USA
    Pediatr Blood Cancer 59:1266-74. 2012
    ..SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels...
  3. pmc Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program
    Richard Gorlick
    The Children s Hospital at Montefiore, Bronx, New York, USA
    Pediatr Blood Cancer 59:518-24. 2012
    ..MK-2206 is a small molecule allosteric inhibitor of Akt/PKB that is undergoing clinical trials for treatment of cancer...
  4. pmc Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier
    Rui Yang
    Department of Pediatrics and Molecular Pharmacology R, Y, R, G, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, NY 10461, USA
    BMC Cancer 8:124. 2008
    ..Heavy promoter methylation was previously identified as a basis for the complete silencing of RFC in MDA-MB-231 breast cancer cells, its role and prevalence in RFC transcription regulation are, however, not widely studied...
  5. doi request reprint Current concepts on the molecular biology of osteosarcoma
    Richard Gorlick
    The Albert Einstein College of Medicine of Yeshiva University, The Children s Hospital at Montefiore, 3415 Bainbridge Avenue, Rosenthal 3rd Floor, Bronx, NY 10467, USA
    Cancer Treat Res 152:467-78. 2009
    ..In this presentation the genetic alterations present in osteosarcoma, issues related to the cell of origin and bone differentiation will be reviewed along with the recent results of preclinical drug screening...
  6. doi request reprint Osteosarcoma
    Richard Gorlick
    Department of Pediatrics and Molecular Pharmacology, The Albert Einstein College of Medicine, Yeshiva University, Department of Pediatrics, Children s Hospital at Montefiore, Bronx, NY 10467, USA
    J Bone Miner Res 25:683-91. 2010
    ..Even in the absence of a more fundamental understanding of osteosarcoma, association studies and preclinical drug testing may yield clinically relevant information...
  7. ncbi request reprint Leydig cell tumor after treatment for Ewing's sarcoma
    Linda J Butros
    Department of Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA
    Pediatr Blood Cancer 49:1008-10. 2007
    ..Additional monitoring for second malignancies may become appropriate as long-term survival continues to improve for patients with Ewing's sarcoma...
  8. ncbi request reprint Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience
    Alexander J Chou
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:2214-21. 2005
    ..Overall survival after recurrence of osteosarcoma (OS) is < 30%. The authors reported their experience treating recurrent OS at the time of first recurrence (R1)...
  9. ncbi request reprint Impairments in antifolate transport are common in retinoblastoma tumor samples
    Richard G Gorlick
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Pediatr Blood Cancer 50:573-6. 2008
    ..Identification of effective chemotherapy agents for retinoblastoma that are not associated with an elevated risk of secondary malignancy would be beneficial...
  10. ncbi request reprint Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience
    LeLe Aung
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 95:1728-34. 2002
    ..The authors investigated the incidence and relative risk of secondary malignant neoplasms in long-term survivors of osteosarcoma...

Research Grants7

  1. ANTIFOLATE RESISTANCE OSTEOSARCOMA
    Richard Gorlick; Fiscal Year: 2001
    ..These studies may define the incidence of intrinsic and acquired methotrexate resistance in tumor samples and suggest the use of new antifolates and therapeutic strategies in the treatment of osteosarcoma. ..
  2. Antifolate Resistance in Osteosarcoma
    Richard Gorlick; Fiscal Year: 2007
    ....